National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Decitabine (Dacogen®) is indicated for AML in patients who are >65yrs who are not candidates for standard induction therapy

Rapid Review

Commenced Completed Outcome
8/11/2012 13/12/2012 Full Pharmacoeconomic Assessment Recommended

05/12/2013  Following additional commercial discussions the HSE has approved reimbursement of Decitabine (Dacogen®) in the hospital setting.